Precigen

Precigen, Inc (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Precigen, Inc.
Traded asNASDAQ: PGEN
Russell 2000 Component
IndustryBiotechnology
FoundedMay 21, 1998 (1998-05-21)
Headquarters
Germantown
Websiteprecigen.com

Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.[1][2] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[3]

History

In 2015, Intrexon purchased Oxitec, a maker of gene drive technology for $160 million.[4] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.[5][6] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[7][8] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.[6]

References
  1. "Intrexon Corporation: Private Company Information". Bloomberg. Retrieved 2017-06-26.
  2. "Intrexon Corp (XON) Company Profile". Reuters.com. Retrieved 2017-06-26.
  3. "FAQ | Intrexon". Intrexon InvestorRoom. Retrieved 2018-03-28.
  4. Nickel, Rod (15 September 2015). "Market turbulence or not, North American investors plow into farm tech". Reuters. Retrieved 9 October 2015.
  5. "PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS". FDA. Retrieved 6 April 2020.
  6. Gilgore, Sara (6 January 2020). "Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug". American City Business Journals. Retrieved 6 April 2020.
  7. "INTREXON CORPORATION IS NOW PRECIGEN, INC". Precigen. Retrieved 6 April 2020.
  8. Helmstetter, Micheal (30 March 2020). "The Promise And Fear Of Gene Editing". Forbes. Retrieved 6 April 2020.

Official website

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.